ALIM Alimera Sciences Inc.

0.98
-0.02  -2%
Previous Close 1
Open 1
Price To Book -2.51
Market Cap 68677300
Shares 70,078,878
Volume 36,296
Short Ratio
Av. Daily Volume 76,554

NewsSee all news

  1. Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
  2. Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
  3. Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial — Fundamental Analysis, Key Performance Indications
  4. Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT
  5. Alimera Sciences to Present at Upcoming Investor Conferences

SEC filingsSee all SEC filings

  1. 8-K - Current report 181219223
  2. 8-K - Current report 181207063
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171167
  4. 8-K - Current report 181161505
  5. 8-K - Current report 181054402

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
  2. Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
  3. Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial — Fundamental Analysis, Key Performance Indications
  4. Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT
  5. Alimera Sciences to Present at Upcoming Investor Conferences
  6. Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates
  7. Alimera Sciences: 3Q Earnings Snapshot
  8. Alimera Sciences Reports Third Quarter 2018 Results
  9. Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018
  10. Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology
  11. How Alimera Sciences Inc (NASDAQ:ALIM) Can Impact Your Portfolio Volatility
  12. Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
  13. Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting
  14. Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock
  15. Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference
  16. Alimera Sciences to Present at the Annual B. Riley Healthcare Conference
  17. Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
  18. Edited Transcript of ALIM earnings conference call or presentation 31-Jul-18 1:00pm GMT
  19. Alimera Sciences, Inc. to Host Earnings Call

SEC Filings

  1. 8-K - Current report 181219223
  2. 8-K - Current report 181207063
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171167
  4. 8-K - Current report 181161505
  5. 8-K - Current report 181054402
  6. 8-K - Current report 181053778
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988661
  8. 8-K - Current report 18984777
  9. 8-K - Current report 18978519
  10. 8-K - Current report 18914939